HBOT Conversations:
Dr. Paul Harch & Inflammation
Dr. Paul G. Harch, M.D. has used hyperbaric oxygen therapy to treat more than 100 different conditions, including stroke, dementia, autism, and traumatic brain injury. His goal is to help his patients get their lives back using hyperbaric oxygen therapy.
He is the author of The Oxygen Revolution and is considered an International expert and pioneer in the field of Hyperbaric Oxygen Therapy (HBOT). His informative, and comprehensive guide on HBOT has helped countless souls better understand what HBOT is and how it directly affects the body at the genetic level.
This episode on Inflammation is the first in a 9 episode series that will be released weekly with Dr. Harch.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with special guest and HBOT expert, Dr. Paul G. Harch, MD. This is the first of nine episodes with Dr. Harch examining the God-given miracle of Hyperbaric Oxygen Therapy.
In this episode, we dive into how HBOT is a game-changer for inflammation. Harch explains that inflammation is the driving factor for countless chronic illnesses, but thankfully Hyperbaric Oxygen Therapy is a natural proven way to suppress inflammation.
Harch summarizes a fascinating study done in 2008, by Dr. Cassandra Godman. Her team took skin biopsies and extracted the normal tissue, then they examined the cells that lined the tiniest blood vessels in the tissue. Next, they put these cells in a petri dish and put them in a hyperbaric chamber and gave him a single hyperbaric treatment. Afterwards, they did a mass gene array analysis for 48 hours. What happened next was ground-breaking in better understanding the role that HBOT has on inflammation.
At the end of 24 hours 8,101 of our 19,000 protein coding genes in our 23 chromosomes were either significantly turned on or turned off & suppressed. That single HBOT treatment turned on the anti-inflammatory genes and the growth and repair hormone genes, and the largest cluster suppressed were the pro-inflammatory genes.
Our inflammatory reaction is inescapable when an injury occurs. But, when the patient receives hyperbaric oxygen therapy treatment after an injury (the sooner the better), it can have an overwhelming positive influence on the inflammatory reaction at any place along the spectrum. Harch continues to explain that the anti-inflammatory effects of hyperbaric oxygen are wide-ranging.
Harch spoke of the Navy’s experience with Hyperbaric Oxygen Therapy, as the Navy really kind of dominated this field for many years. The Navy reported that if you can get someone in a chamber within one hour of coming out of the water – when they’re symptomatic for decompression sickness – then the first hyperbaric treatment is curative in 90% of cases. Everyone thought that HBOT was treating bubbles in the brain at that point, but the reality is they were treating inflammation. We now know that it’s the inflammatory reaction in the brain after the bubbles passed that Hyperbaric Oxygen Therapy is treating; not the bubbles.
HBOT isn’t new, it dates back well over a hundred years. It’s still misunderstood, because many believe that HBOT therapy is a treatment for diseases. But, the reality is that HBOT is a treatment for disease processes, and it’s these processes that cause the diseases. We treat the inflammation that causes the disease processes, and in turn we treat the disease. That’s the power of Hyperbaric Oxygen Therapy.
Stay tuned for all nine episodes that will be release each Friday for the next eight weeks.
Guest
Dr. Paul G. Harch, MD
Dr. Paul G. Harch, M.D. is a clinician in emergency medicine and hyperbaric medicine who is the former director of the University Medical Center Hyperbaric Medicine Department and LSU Hyperbaric Medicine Fellowship. Currently, he is a Clinical Professor of Medicine in the Section of Emergency Medicine at LSU School of Medicine in New Orleans. He graduated from the Johns Hopkins University School of Medicine after graduating from the University of California at Irvine with magna cum laude/Phi Beta Kappa honors.
Dr. Harch initiated and continues to be a private practice that has resulted in the largest case experience in neurological hyperbaric medicine in the world. In this practice, he adapted the concepts of conventional hyperbaric oxygen therapy to wounds in the central nervous system, which spawned the subsequent academic and research practice. Harch HBOT is the best place to receive oxygen therapy treatments, and patients have traveled from more than 50 countries to be treated by Dr. Harch himself.
Harch HBOT – Hyperbaric Oxygen Therapy Clinic
5216 Lapalco Blvd.
Marrero, LA
504-309-4948
hbot@hbot.com
https://hbot.com/
Subscribe Now, It’s Free !
Recent HBOT News
The Effect of Hyperbaric Oxygen Therapy on Myocardial Perfusion after the Implantation of Drug-Eluting Stents.
Abstract: The study is to investigate hyperbaric oxygen therapy (HBOT) on myocardial perfusion of patients after the implantation of drug-eluting stents (DES) METHODS: From December 2013 to December 2015, a total of 115 patients with CAD who received DES implantation...
Clinical Trial – Influence of Injection Rate of Intrathecal Mixture of Local Anesthesia on Hypotension in Cesarean Section
Hypotension is the most common complication of neuraxial anesthesia in obstetric patients and
its prevalence in cesarean section is about 50-90%. Maternal hypotension causes unpleasant
symptoms such as nausea, vomiting, loss of consciousness, respiratory depression, and cardiac
arrest. Hypotension may reduce placental perfusion and result in fetal acidosis and
neurological injury. Several techniques have been proposed to prevent hypotension.
The recommended spinal block height to ensure patient comfort for Cesarean delivery is T4-6.
Clinically, it is desirable that the spread of local anesthetic through the cerebrospinal
fluid (CSF) achieves a sensory level no higher than the T4 dermatome to avoid extensive
sympathetic block. It is also important that the spinal block level be no lower than T6 to
avoid patient discomfort during peritoneal manipulation and uterine exteriorization. The
effect of injection speed on spread of spinal anesthesia is controversial. Several studies
have demonstrated more extensive spread with faster injection while others report either
greater spread with slower injection, or no difference. Slow injection of hyperbaric
bupivacaine 10 mg over 60 and 120 sec has been shown to reduce the incidence and severity of
hypotension during Cesarean delivery under spinal anesthesia.
Clinical Trial – Enhanced Recovery After Surgery for Emergency Caesarean Deliveries
Caesarean section (CS) constitutes a large proportion of the total surgical volume in
low-income countries. This rate comes with challenges including surgical complications,
shortage of beds, and consequently long waiting time for operations and high costs. These
have led to the adoption of ERAS in developed countries in a bid to save costs by reducing
hospital length of stay without compromising the health of the mother and her baby.